{Reference Type}: Journal Article
{Title}: Ribavirin extends the lifespan of Caenorhabditis elegans through AMPK-TOR Signaling.
{Author}: Zhang G;Liu H;Xue T;Kong X;Tian D;Luo L;Yang Y;Xu K;Wei Y;Zhuang Z;
{Journal}: Eur J Pharmacol
{Volume}: 946
{Issue}: 0
{Year}: May 2023 5
{Factor}: 5.195
{DOI}: 10.1016/j.ejphar.2023.175548
{Abstract}: Aging is a process accompanied by widespread degenerative changes which are a major cause of human disease and disability. One goal of aging research is to develop interventions or drugs that can extend organism lifespan and treat age-related diseases. Here, we report the identification of a broad spectrum anti-viral agent, ribavirin, as a potential pharmacological aging intervention. Ribavirin extended the lifespan and healthspan of Caenorhabditis elegans by inhibiting Target of Rapamycin (TOR) signaling and activating AMP-activated protein kinase (AMPK). Moreover, our data indicate that ribavirin activated AMPK by reducing the levels of adenosine triphosphate (ATP) and lysosomal v-ATPase-Ragulator-AXIN Complex. Thus, our studies successfully identify ribavirin as a potential anti-aging drug, and indicate that its anti-aging effect is mediated via AMPK-TOR signaling.